An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2018 According to the Ionis Pharmaceuticals media release, data from this study will be presented at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
    • 26 Mar 2018 According to the Ionis Pharmaceuticals media release, new data from this study will be presented at the 16th International Symposium on Amyloidosis (ISA) 2018.
    • 26 Mar 2018 Results presented in the Ionis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top